Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Aug;33(8):1329–1334. doi: 10.1128/aac.33.8.1329

Teicoplanin in the treatment of gram-positive-bacterial endocarditis.

P Martino 1, M Venditti 1, A Micozzi 1, C Brandimarte 1, G Gentile 1, C Santini 1, P Serra 1
PMCID: PMC172649  PMID: 2529815

Abstract

Intravenous teicoplanin has been used to treat 23 cases of gram-positive-bacterial endocarditis, usually with 3 to 7 mg/kg every 12 h on the first day, followed by 3 to 7 mg/kg every 24 h. For some cases (staphylococcal and enterococcal endocarditis), the dosage was 8 to 14.4 mg/kg per day and/or other antibiotics were given. The mean duration was 48.2 days (range, 23 to 130 days). Of 23 patients, 21 (91.3%) had negative cultures or were cured. A total of 18 patients were treated with teicoplanin alone; of these, 4 had surgery, and all (except 2 who relapsed) were cured. Teicoplanin was combined with one or more antibiotics in five cases; in all cases appropriate cultures were negative, but three patients died during therapy or follow-up. Mild renal impairment was seen in two patients; both were receiving teicoplanin in combination with an aminoglycoside. We conclude that intravenous teicoplanin administered once a day at doses of 7 to 14 mg/kg per day is well tolerated, easy to administer, and may represent an efficacious therapy for gram-positive-bacterial endocarditis.

Full text

PDF
1334

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Calain P., Krause K. H., Vaudaux P., Auckenthaler R., Lew D., Waldvogel F., Hirschel B. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis. 1987 Feb;155(2):187–191. doi: 10.1093/infdis/155.2.187. [DOI] [PubMed] [Google Scholar]
  2. Cavenaghi L., Corti A., Cassani G. Comparison of the solid phase enzyme receptor assay (SPERA) and the microbiological assay for teicoplanin. J Hosp Infect. 1986 Mar;7 (Suppl A):85–89. doi: 10.1016/0195-6701(86)90012-5. [DOI] [PubMed] [Google Scholar]
  3. Chambers H. F., Sande M. A. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984 Jul;26(1):61–64. doi: 10.1128/aac.26.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cynamon M. H., Granato P. A. Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci. Antimicrob Agents Chemother. 1982 Mar;21(3):504–505. doi: 10.1128/aac.21.3.504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Galetto D. W., Boscia J. A., Kobasa W. D., Kaye D. Teicoplanin compared with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis. J Infect Dis. 1986 Jul;154(1):69–75. doi: 10.1093/infdis/154.1.69. [DOI] [PubMed] [Google Scholar]
  6. Garvey G. J., Neu H. C. Infective endocarditis--an evolving disease. A review of endocarditis at the Columbia-Presbyterian Medical Center, 1968-1973. Medicine (Baltimore) 1978 Mar;57(2):105–127. [PubMed] [Google Scholar]
  7. Gilbert B. W., Haney R. S., Crawford F., McClellan J., Gallis H. A., Johnson M. L., Kisslo J. A. Two-dimensional echocardiographic assessment of vegetative endocarditis. Circulation. 1977 Feb;55(2):346–353. doi: 10.1161/01.cir.55.2.346. [DOI] [PubMed] [Google Scholar]
  8. Glupczynski Y., Lagast H., Van der Auwera P., Thys J. P., Crokaert F., Yourassowsky E., Meunier-Carpentier F., Klastersky J., Kains J. P., Serruys-Schoutens E. Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 1986 Jan;29(1):52–57. doi: 10.1128/aac.29.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jadeja L., Fainstein V., LeBlanc B., Bodey G. P. Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroids. Antimicrob Agents Chemother. 1983 Aug;24(2):145–146. doi: 10.1128/aac.24.2.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kaye D. Changing pattern of infective endocarditis. Am J Med. 1985 Jun 28;78(6B):157–162. doi: 10.1016/0002-9343(85)90378-x. [DOI] [PubMed] [Google Scholar]
  11. Murray B. E., Karchmer A. W., Moellering R. C., Jr Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms. Am J Med. 1980 Dec;69(6):838–848. doi: 10.1016/s0002-9343(80)80009-x. [DOI] [PubMed] [Google Scholar]
  12. Neu H. C., Labthavikul P. In vitro activity of teichomycin compared with those of other antibiotics. Antimicrob Agents Chemother. 1983 Sep;24(3):425–428. doi: 10.1128/aac.24.3.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pauluzzi S., Del Favero A., Menichetti F., Baratta E., Moretti V. M., Di Filippo P., Pasticci M. B., Guerciolini R., Patoia L., Frongillo R. F. Treatment of infections by staphylococci and other gram-positive bacteria with teicoplanin: an open study. J Antimicrob Chemother. 1987 Sep;20(3):431–438. doi: 10.1093/jac/20.3.431. [DOI] [PubMed] [Google Scholar]
  14. Robbins M. J., Soeiro R., Frishman W. H., Strom J. A. Right-sided valvular endocarditis: etiology, diagnosis, and an approach to therapy. Am Heart J. 1986 Jan;111(1):128–135. doi: 10.1016/0002-8703(86)90564-8. [DOI] [PubMed] [Google Scholar]
  15. Rosen P., Armstrong D. Infective endocarditis in patients treated for malignant neoplastic diseases: a postmortem study. Am J Clin Pathol. 1973 Aug;60(2):241–250. doi: 10.1093/ajcp/60.2.241. [DOI] [PubMed] [Google Scholar]
  16. Serra P., Brandimarte C., Martino P., Carlone S., Giunchi G. Synergistic treatment of enterococcal endocarditis: in vitro and in vivo studies. Arch Intern Med. 1977 Nov;137(11):1562–1567. [PubMed] [Google Scholar]
  17. Sullam P. M., Täuber M. G., Hackbarth C. J., Sande M. A. Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1985 Jan;27(1):135–136. doi: 10.1128/aac.27.1.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Varaldo P. E., Debbia E., Schito G. C. In vitro activity of teichomycin and vancomycin alone and in combination with rifampin. Antimicrob Agents Chemother. 1983 Mar;23(3):402–406. doi: 10.1128/aac.23.3.402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Verbist L., Tjandramaga B., Hendrickx B., Van Hecken A., Van Melle P., Verbesselt R., Verhaegen J., De Schepper P. J. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother. 1984 Dec;26(6):881–886. doi: 10.1128/aac.26.6.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Von Reyn C. F., Levy B. S., Arbeit R. D., Friedland G., Crumpacker C. S. Infective endocarditis: an analysis based on strict case definitions. Ann Intern Med. 1981 Apr;94(4 Pt 1):505–518. doi: 10.7326/0003-4819-94-4-505. [DOI] [PubMed] [Google Scholar]
  21. Webster A., Wilson A. P., Williams A. H., Treasure T., Grüneberg R. N. The use of a new glycopeptide antibiotic, teicoplanin, in the treatment of bacterial endocarditis. Postgrad Med J. 1987 Aug;63(742):621–624. doi: 10.1136/pgmj.63.742.621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Weinstein M. P., Stratton C. W., Ackley A., Hawley H. B., Robinson P. A., Fisher B. D., Alcid D. V., Stephens D. S., Reller L. B. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med. 1985 Feb;78(2):262–269. doi: 10.1016/0002-9343(85)90436-x. [DOI] [PubMed] [Google Scholar]
  23. Wilson W. R., Geraci J. E. Treatment of streptococcal infective endocarditis. Am J Med. 1985 Jun 28;78(6B):128–137. doi: 10.1016/0002-9343(85)90375-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES